|
| |
| | | 67862 | | 08.02.2021 | | Eli Lilly (Suisse) SA | | | | | | | 19.12.2029 | | | | | | 07.16.10. | | | | 07.16.10. | | IP |
| | Seq.-No. | Product | Description | Galenic form | ATC-classification | |
|---|
| 01 | Retsevmo 40 mg | gélules | Capsules (Selpercatinibum 40 mg) | L01EX22 | CI | | 02 | Retsevmo 80 mg | gélules | Capsules (Selpercatinibum 80 mg) | L01EX22 | CI |
|
|
|
